$329.07
2.59%
Nasdaq, Tue, Sep 23 2025
ISIN
US07725L1026
Symbol
BGNE

BeiGene Ltd. Sponsored ADR Stock price

$329.07
+20.44 6.62% 1M
+75.87 29.96% 6M
+144.36 78.15% YTD
+127.76 63.46% 1Y
+190.43 137.36% 3Y
+54.39 19.80% 5Y
+300.75 1,061.97% 10Y
+300.75 1,061.97% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-8.75 2.59%
ISIN
US07725L1026
Symbol
BGNE
Industry

Key metrics

Basic
Market capitalization
$42.2b
Enterprise Value
$40.7b
Net debt
positive
Cash
$2.5b
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 2,996.0
P/S
9.2 | 7.9
EV/Sales
8.9 | 7.6
EV/FCF
215.5
P/B
12.0
Financial Health
Equity Ratio
56.4%
Return on Equity
-20.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$4.6b | $5.3b
EBITDA
- | $245.1m
EBIT
$-99.7m | $63.2m
Net Income
$-232.2m | -
Free Cash Flow
$189.0m
Growth (TTM | estimate)
Revenue
47.7% | 39.6%
EBITDA
- | 147.7%
EBIT
89.5% | 110.6%
Net Income
62.3% | -
Free Cash Flow
113.3%
Margin (TTM | estimate)
Gross
85.4%
EBITDA
- | 4.6%
EBIT
-2.2%
Net
-5.0% | -
Free Cash Flow
4.1%
More
EPS
$-0.2
FCF per Share
-
Short interest
2.6%
Employees
11k
Rev per Employee
$350.0k
Show more

Is BeiGene Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy
92%
Hold
8%

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,603 4,603
48% 48%
100%
- Direct Costs 673 673
37% 37%
15%
3,930 3,930
50% 50%
85%
- Selling and Administrative Expenses 1,972 1,972
18% 18%
43%
- Research and Development Expense 2,079 2,079
9% 9%
45%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -100 -100
89% 89%
-2%
Net Profit -232 -232
62% 62%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about BeiGene Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeiGene Ltd. Sponsored ADR Stock News

Neutral
Business Wire
5 months ago
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 pat...
Neutral
Business Wire
6 months ago
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination...

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office Cayman Islands
CEO John Oyler
Employees 11,000
Founded 2010
Website www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today